Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors

Preliminary results and promising directions

M. J. Glantz, H. Choy, C. M. Kearns, W. Akerley, M. J. Egorin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In a phase I study, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was given weekly by 3-hour infusion for 6 weeks concurrent with daily cranial irradiation as initial treatment for patients with newly diagnosed astrocytic brain tumors. The primary goal of the study was to establish the maximum tolerated dose of paclitaxel when administered by this schedule. Sixty patients were entered into the study and received at least one course of therapy. Fifty-six patients completed treatment. The treatment regimen was well tolerated, with minimal hematologic toxicity. Peripheral neuropathy was dose-limiting. Median survival was 9.2 months for patients with glioblastoma multiforme and has not been reached for patients with anaplastic astrocytoma or astrocytoma. The maximum tolerated dose of paclitaxel in this study was 250 mg/m2 administered weekly. However, because five of six patients receiving this dose of paclitaxel developed peripheral neuropathy, and because patients with brain tumors may adapt to a superimposed neuropathy less well than patients without pre-existing nervous system dysfunction, we propose 225 mg/m2 as the recommended dose for subsequent phase II trials.

Original languageEnglish (US)
Pages (from-to)26-32
Number of pages7
JournalSeminars in Oncology
Volume22
Issue number5 SUPPL. 12
StatePublished - 1995

Fingerprint

Cranial Irradiation
Paclitaxel
Brain Neoplasms
Outpatients
Maximum Tolerated Dose
Astrocytoma
Peripheral Nervous System Diseases
Direction compound
Therapeutics
Glioblastoma
Nervous System
Appointments and Schedules
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors : Preliminary results and promising directions. / Glantz, M. J.; Choy, H.; Kearns, C. M.; Akerley, W.; Egorin, M. J.

In: Seminars in Oncology, Vol. 22, No. 5 SUPPL. 12, 1995, p. 26-32.

Research output: Contribution to journalArticle

@article{77f4ff248cc649908590a3ce7055bab0,
title = "Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: Preliminary results and promising directions",
abstract = "In a phase I study, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was given weekly by 3-hour infusion for 6 weeks concurrent with daily cranial irradiation as initial treatment for patients with newly diagnosed astrocytic brain tumors. The primary goal of the study was to establish the maximum tolerated dose of paclitaxel when administered by this schedule. Sixty patients were entered into the study and received at least one course of therapy. Fifty-six patients completed treatment. The treatment regimen was well tolerated, with minimal hematologic toxicity. Peripheral neuropathy was dose-limiting. Median survival was 9.2 months for patients with glioblastoma multiforme and has not been reached for patients with anaplastic astrocytoma or astrocytoma. The maximum tolerated dose of paclitaxel in this study was 250 mg/m2 administered weekly. However, because five of six patients receiving this dose of paclitaxel developed peripheral neuropathy, and because patients with brain tumors may adapt to a superimposed neuropathy less well than patients without pre-existing nervous system dysfunction, we propose 225 mg/m2 as the recommended dose for subsequent phase II trials.",
author = "Glantz, {M. J.} and H. Choy and Kearns, {C. M.} and W. Akerley and Egorin, {M. J.}",
year = "1995",
language = "English (US)",
volume = "22",
pages = "26--32",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 12",

}

TY - JOUR

T1 - Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors

T2 - Preliminary results and promising directions

AU - Glantz, M. J.

AU - Choy, H.

AU - Kearns, C. M.

AU - Akerley, W.

AU - Egorin, M. J.

PY - 1995

Y1 - 1995

N2 - In a phase I study, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was given weekly by 3-hour infusion for 6 weeks concurrent with daily cranial irradiation as initial treatment for patients with newly diagnosed astrocytic brain tumors. The primary goal of the study was to establish the maximum tolerated dose of paclitaxel when administered by this schedule. Sixty patients were entered into the study and received at least one course of therapy. Fifty-six patients completed treatment. The treatment regimen was well tolerated, with minimal hematologic toxicity. Peripheral neuropathy was dose-limiting. Median survival was 9.2 months for patients with glioblastoma multiforme and has not been reached for patients with anaplastic astrocytoma or astrocytoma. The maximum tolerated dose of paclitaxel in this study was 250 mg/m2 administered weekly. However, because five of six patients receiving this dose of paclitaxel developed peripheral neuropathy, and because patients with brain tumors may adapt to a superimposed neuropathy less well than patients without pre-existing nervous system dysfunction, we propose 225 mg/m2 as the recommended dose for subsequent phase II trials.

AB - In a phase I study, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was given weekly by 3-hour infusion for 6 weeks concurrent with daily cranial irradiation as initial treatment for patients with newly diagnosed astrocytic brain tumors. The primary goal of the study was to establish the maximum tolerated dose of paclitaxel when administered by this schedule. Sixty patients were entered into the study and received at least one course of therapy. Fifty-six patients completed treatment. The treatment regimen was well tolerated, with minimal hematologic toxicity. Peripheral neuropathy was dose-limiting. Median survival was 9.2 months for patients with glioblastoma multiforme and has not been reached for patients with anaplastic astrocytoma or astrocytoma. The maximum tolerated dose of paclitaxel in this study was 250 mg/m2 administered weekly. However, because five of six patients receiving this dose of paclitaxel developed peripheral neuropathy, and because patients with brain tumors may adapt to a superimposed neuropathy less well than patients without pre-existing nervous system dysfunction, we propose 225 mg/m2 as the recommended dose for subsequent phase II trials.

UR - http://www.scopus.com/inward/record.url?scp=0028882781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028882781&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 26

EP - 32

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 12

ER -